Filing Details
- Accession Number:
- 0001209191-20-013039
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-26 16:39:23
- Reporting Period:
- 2020-02-24
- Accepted Time:
- 2020-02-26 16:39:23
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1789815 | Ourania Tatsis | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Svp, Cro | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2020-02-24 | 1,036 | $239.23 | 14,034 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2020-02-25 | 416 | $229.57 | 13,618 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-25 | 160 | $231.82 | 13,458 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-25 | 80 | $232.43 | 13,378 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-25 | 240 | $234.43 | 13,138 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-25 | 160 | $235.39 | 12,978 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-25 | 240 | $237.81 | 12,738 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | F | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $229.57 (range $229.15 to $229.91).
- Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $231.82 (range $231.27 to $232.37).
- Open market sales reported on this line occurred at a weighted average price of $234.43 (range $234.14 to $234.89).
- Open market sales reported on this line occurred at a weighted average price of $235.39 (range $235.33 to $235.44).
- Open market sales reported on this line occurred at a weighted average price of $237.81 (range $237.24 to $238.18).
Billionaire Hedge Funds
